Rice bran for radiation-related mouth sores in head and neck cancer
Official title: Effects of Rice Bran on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer and Its Impact on the Quality of Life
Run by German University in Cairo · NCT07242859 · Data updated 2026-11-12
This trial will try rice bran supplements during radiation to see if adults with head and neck cancer have fewer or less severe mouth sores.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | German University in Cairo Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | January 15, 2023 |
| Main results expected | November 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | November 21, 2025 |
| Trial ID | NCT07242859 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with non-metastatic head and neck squamous cell carcinoma scheduled for IMRT (radical or adjuvant) with ECOG 0–2, with or without concurrent chemotherapy, who can provide written consent are eligible.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have oral lesions unrelated to their cancer or treatment, are taking drugs that cause oral lesions or anticoagulants, or are receiving other unapproved investigational anticancer agents are unlikely to benefit from this intervention in the trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Radiation-induced oral mucositis causes painful inflammation and ulcers in the mouths of many patients receiving radiation for head and neck cancer. This interventional trial gives rice bran supplements concurrently with IMRT to see whether the antioxidant and anti-inflammatory components reduce the incidence, duration, or severity of mucositis. Outcomes include clinical mucositis measures and patient-reported quality of life during and after radiation. The goal is to determine whether a low-cost dietary supplement can improve supportive care for these patients.
Why it matters
Potential benefit: If successful, rice bran could offer a low-cost, accessible way to reduce the severity and duration of radiation-induced oral mucositis and improve patients' ability to eat and speak during treatment.
How similar studies have gone: Some antioxidant or anti-inflammatory dietary supplements have shown mixed effects on radiation-induced mucositis, while rice bran specifically has limited clinical trial data and remains relatively untested in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients of age 18 years old tor more * Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors. * Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2 * Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy * Ready to provide written informed consent Exclusion Criteria: * Receiving any other approved or investigational anti-cancer agent than those specified in this study. * Pregnant or breastfeeding female patients * Patients who have oral lesions unrelated to treatment or cancer, * Patients who are on drugs that could cause oral lesions or are using anticoagulants.
Where it's running
-
German university in cairo
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Christina Milad Lobos, Master
- Email: Krstina.Bqtr@pharm.aun.edu.eg
- Phone: +20 1005279101
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pravastatin for long-term swallowing problems after head and neck radiotherapy
This study will test whether taking pravastatin daily for 12 months can improve long-term swallowing problems in people who had radiotherapy for head and neck cancer.
-
Zanidatamab for solid tumors with HER2 changes
This study will try zanidatamab, an anti-HER2 drug, in adults with advanced endometrial, colorectal, head and neck, sarcoma, or non-small cell lung cancer whose tumors have specific HER2 changes.
-
Proactive risk-based coordination to shorten time from surgery to post-operative radiation for head and neck cancer
This pilot tests whether an automated care-coordination system (PRONTO-HN) can help adults with oral or laryngeal squamous cell carcinoma begin post-operative radiotherapy within 42 days after surgery.
-
Tislelizumab with chemotherapy given before surgery in 2 or 4 cycles for locally advanced, resectable head and neck squamous cell cancer
This trial tests whether 2 or 4 cycles of neoadjuvant tislelizumab plus chemotherapy can be given safely and more effectively before surgery.
-
Reversing radiotherapy-related fibrosis and lymphedema in head and neck cancer survivors
This trial will test whether adding one of several drugs (pravastatin, pentoxifylline, ketoprofen, or pirfenidone) to standard care can prevent or reduce radiation-related fibrosis and lymphedema in people treated for head and neck cancer.
-
Houyanqing oral liquid to prevent and treat radiation mouth sores in nasopharyngeal cancer
This phase 3 trial will test whether adding Houyanqing oral liquid to standard care can prevent or lessen radiation-caused mouth sores in adults receiving radiotherapy for nasopharyngeal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.